Celldex Couldn’t Sway FDA On Rintega
This article was originally published in The Pink Sheet Daily
Executive Summary
Although it yielded impressive survival data compared to standard of care, the Phase II ReACT study was not powered for efficacy, so FDA is requiring Phase III data as well despite the need in glioblastoma.
You may also be interested in...
Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
Celldex presented positive data from a Phase II study testing the therapeutic cancer vaccine Rintega in patients with EGFRvIII-positive recurrent glioblastoma, including a survival advantage, at ASCO.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.